PUBLISHER: TechNavio | PRODUCT CODE: 2126097
PUBLISHER: TechNavio | PRODUCT CODE: 2126097
Global Women Health Therapeutics Market 2026-2030
The global women health therapeutics market is forecasted to grow by USD 39597.9 mn during 2025-2030, accelerating at a CAGR of 6.1% during the forecast period. The report on the global women health therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising awareness of women health, expansion of nonhormonal therapeutics, increasing investments in therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 5.7% |
| CAGR | 6.1% |
| Incremental Value | $39597.9 mn |
Technavio's global women health therapeutics market is segmented as below:
By Type
- Fertility
- Oncology
- Menopause
- Infection
- Others
By Age Group
- Elderly women
- Adult women
- Adolescents
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the rising demand for targeted therapeutics as one of the prime reasons driving the global women health therapeutics market growth during the next few years. Also, expansion of menopause management solutions and integration of digital health technologies will lead to sizable demand in the market.
The report on the global women health therapeutics market covers the following areas:
- Global women health therapeutics market sizing
- Global women health therapeutics market forecast
- Global women health therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global women health therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Biocon Biologics Ltd., Cipla Inc., Eli Lilly and Co., Ferring BV, Genentech Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Novartis AG, Organon and Co., Pfizer Inc., Sanofi SA, Viatris Inc., Zydus Lifesciences Ltd.. Also, the global women health therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Age Group
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Women Health Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Women Health Therapeutics Market 2020 - 2024 ($ million)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.3 Age Group segment analysis 2020 - 2024
- Historic Market Size - Age Group Segment 2020 - 2024 ($ million)
- 5.4 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Womens Health Therapeutics Market
- 6.2 Impact of geopolitical conflicts on Global Womens Health Therapeutics Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 Fertility - Market size and forecast 2025-2030
- 8.4 Oncology - Market size and forecast 2025-2030
- 8.5 Menopause - Market size and forecast 2025-2030
- 8.6 Infection - Market size and forecast 2025-2030
- 8.7 Others - Market size and forecast 2025-2030
- 8.8 Market opportunity by Type
- Market opportunity by Type ($ million)
9 Market Segmentation by Age Group
- 9.1 Market segments
- 9.2 Comparison by Age Group
- 9.3 Elderly women - Market size and forecast 2025-2030
- 9.4 Adult women - Market size and forecast 2025-2030
- 9.5 Adolescents - Market size and forecast 2025-2030
- 9.6 Market opportunity by Age Group
- Market opportunity by Age Group ($ million)
10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- 10.2 Comparison by Distribution Channel
- 10.3 Hospital pharmacies - Market size and forecast 2025-2030
- 10.4 Retail pharmacies - Market size and forecast 2025-2030
- 10.5 Online pharmacies - Market size and forecast 2025-2030
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Thailand - Market size and forecast 2025-2030
- 12.5.6 Indonesia - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising awareness of women health
- Expansion of nonhormonal therapeutics
- Increasing investments in therapeutics
- 13.2 Market challenges
- Severe inadequacies in clinical research funding
- Complex regulatory hurdles and compliance
- Persistent cultural stigmas and barriers
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Rising demand for targeted therapeutics
- Expansion of menopause management solutions
- Integration of digital health technologies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Abbott Laboratories
- Abbott Laboratories - Overview
- Abbott Laboratories - Business segments
- Abbott Laboratories - Key news
- Abbott Laboratories - Key offerings
- Abbott Laboratories - Segment focus
- SWOT
- 15.5 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.6 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key news
- Astellas Pharma Inc. - Key offerings
- SWOT
- 15.7 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.8 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.9 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- 15.10 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.11 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 15.12 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.13 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.14 Organon and Co.
- Organon and Co. - Overview
- Organon and Co. - Product / Service
- Organon and Co. - Key offerings
- SWOT
- 15.15 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.17 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
- 15.18 Zydus Lifesciences Ltd.
- Zydus Lifesciences Ltd. - Overview
- Zydus Lifesciences Ltd. - Business segments
- Zydus Lifesciences Ltd. - Key news
- Zydus Lifesciences Ltd. - Key offerings
- Zydus Lifesciences Ltd. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
